Short answer · Medically reviewed summary · Last updated: 2026-05-08
TL;DR: Choroideremia is currently the focus of intensive gene therapy research aimed at halting the progression of retinal degeneration caused by mutations in the CHM gene. While several high-profile clinical trials have provided valuable insights into subretinal delivery methods, the field is now transitioning toward optimizing long-term durability and exploring novel therapeutic modalities. What is the current status of Choroideremia gene therapy? The primary research focus for Choroideremia involves using viral vectors to deliver a functional copy of the CHM gene directly into the retinal pigment epithelium.
What are the latest advances in Choroideremia?
Latest advances in Choroideremia: recent research, treatments in development and what they could mean, with sources.
TL;DR: Choroideremia is currently the focus of intensive gene therapy research aimed at halting the progression of retinal degeneration caused by mutations in the CHM gene. While several high-profile clinical trials have provided valuable insights into subretinal delivery methods, the field is now transitioning toward optimizing long-term durability and exploring novel therapeutic modalities.
What is the current status of Choroideremia gene therapy?
The primary research focus for Choroideremia involves using viral vectors to deliver a functional copy of the CHM gene directly into the retinal pigment epithelium. Although phase 2 and 3 clinical trials have demonstrated that Choroideremia gene therapy can be performed safely, results regarding long-term visual acuity improvements remain complex and vary among participants. Researchers are currently analyzing data from these trials to better understand how to optimize dosing and timing for future interventions.
What are the latest research directions for Choroideremia?
Beyond traditional gene replacement, the scientific community is investigating several cutting-edge approaches to treat Choroideremia:
- CRISPR-Cas9 Gene Editing: Early-stage laboratory research is exploring whether gene editing can provide a more permanent correction of the CHM mutation.
- Neuroprotection: Clinical studies are evaluating small molecules designed to protect retinal cells from dying, even if the primary genetic defect persists.
- Stem Cell Therapy: Researchers are looking at whether stem cell-derived retinal pigment epithelium cells could eventually replace damaged tissue in advanced cases of Choroideremia.
How can patients contribute to Choroideremia research?
Active participation is vital for moving the needle on Choroideremia research. Patients can contribute by joining natural history studies, which collect longitudinal data to help scientists design better clinical trials. Currently, 96 people with Choroideremia have joined the DiseaseMaps.org community, providing a platform to share experiences and stay updated on emerging opportunities. To find active trials, patients should regularly check ClinicalTrials.gov using the search term "Choroideremia" to view recruitment status and inclusion criteria.
Next steps
- Consult with a retinal specialist or an ophthalmogeneticist to discuss your specific genetic profile.
- Register with the Choroideremia Research Foundation (CRF) to receive alerts on new studies.
- Monitor ClinicalTrials.gov for updates on phase 1/2 trials.
- Connect with the DiseaseMaps community to learn from the lived experiences of others navigating this condition.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult with a qualified healthcare professional regarding any clinical decisions.
References
- National Institutes of Health (NIH) GARD: Choroideremia (rarediseases.info.nih.gov)
- Orphanet: Choroideremia (orpha.net)
- Choroideremia Research Foundation (curechm.org)
- OMIM: Choroideremia (omim.org)
